Skip to main content

Day: December 5, 2023

Form 8.3 – [musicMagpie plc 04 12 2023] – (CGAML)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY ASSET MANAGEMENT LIMITED (for Discretionary Clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree musicMagpie plc(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position...

Continue reading

U.S. Telemedicine Market Size, Share & Growth Analysis, [2030] | CAGR of 15.1%

As per the report by Fortune Business Insights, the U.S. Telemedicine Market size was USD 38.04 billion in 2022, and is projected to grow at a CAGR of 8.5% during the forecast periodU.S. Telemedicine MarketU.S. Telemedicine Market (2023-2030)Pune, India, Dec. 05, 2023 (GLOBE NEWSWIRE) — The U.S. telemedicine market size was valued at USD 38.04 Billion in 2022 and is projected to grow at a CAGR of 15.1% during the forecast period. Healthcare providers utilize telemedicine to provide care from a distance by identifying disease symptoms and ensuring the situation is controlled. The rising demand for virtual care in the U.S. to manage chronic diseases is estimated to drive market growth during the forecast period. The COVID-19 pandemic positively impacted the U.S. telemedicine market growth. The growth was attributed to...

Continue reading

Thin Film Drugs Market Size, Share & Growth Analysis, [2028] | CAGR of 10.5%

As per the report by Fortune Business Insights, the global Thin Film Drugs Market size is projected to reach USD 16.27 billion in 2028, at a CAGR of 10.5% during the forecast period, 2021-2028Thin Film Drugs MarketForecast 2021-2028Pune, India, Dec. 05, 2023 (GLOBE NEWSWIRE) — Global Thin Film Drugs Market Size was valued at USD 7.35 billion in 2020 and is projected to grow from USD 16.27 billion by 2028 exhibiting a CAGR of 10.5% during forecast period. Increasing Prevalence of Schizophrenia in U.S. to Favor Growth in North America, Ease of Administration of Drugs to Accelerate Growth The global thin film drugs market is set to gain momentum from the rising investments by reputed organizations in research and development activities. Some of them are also engaging in mergers and acquisitions to surge their shares. XPhyto...

Continue reading

Recording of Inbank investor webinar on subordinated bond offering

On 1 December 2023, Inbank held a webinar introducing the public offering of Inbank subordinated bonds in Estonia.  During the webinar, Inbank’s CEO Priit Põldoja and CFO Marko Varik gave an overview of Inbank’s strategy, financials and the subordinated bond offering. Recording of the investor meeting (in Estonian) is available at: https://www.inbank.ee/volakirjad (under the section “Investor seminar”).    Additional information about the public subordinated bond offering can also be found at https://www.inbank.ee/volakirjad.  Additional information:Merit ArvaInbank ASHead of Communicationsmerit.arva@inbank.ee+372 553 3550

Continue reading

Dental Implants Market Size, Share & Growth Analysis, [2030] | 6.7% CAGR

As per the report by Fortune Business Insights, the global Dental Implants Market size is projected to reach USD 6.95 billion in 2030, at a CAGR of 6.7% during the forecast period, 2023-2030Dental Implants MarketDental Implants Market Forecast (2023-2030)Pune, India, Dec. 05, 2023 (GLOBE NEWSWIRE) — The Dental implants market is projected to reach USD 4.42 billion in 2023, with an expected increase to USD 6.95 billion by 2030, exhibiting a CAGR of 6.7% during the forecast period. Dental implants are commonly employed to support dental prosthetics. Rising prevalence of oral disorders worldwide is driving the demand for these implants. Fortune Business Insights™ presents this information in their report titled “Global Dental Implants Market, 2023-2030.”Request a Free Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/dental-implants-market-100443Key...

Continue reading

Mosaic Minerals Announces Closing of Oversubscribed Offering and Option of 113 North

MONTRÉAL, Dec. 05, 2023 (GLOBE NEWSWIRE) — Mosaic Minerals Corporation (CSE: MOC) (“Mosaic” or the “Corporation”) is pleased to announce that it has closed an oversubscribed private placement (the “Offering”), pursuant to which it issued 7,962,500 flow-through units (each a “Unit”) at a price of $0.08 per Unit, for gross proceeds of $637,000. Each Unit consists of:One flow-through share (“FT Share”) of the Corporation One-half common share warrant.Each whole warrant (a “Warrant”) can be exercised to purchase one Share at a price of $0.12 per Share for a period of 18 months ending June 4, 2025. An aggregate number of 3,981,250 Warrants have been issued as part of the Offering. A 7% cash commission will be paid to an unrelated third party as an intermediary. The proceeds will be used for exploration work on the Amanda lithium...

Continue reading

Branded Legacy, Inc. (BLEG) Expands Portfolio with Comprehensive Acquisition of MariJ Pharmaceuticals Inc, Including Licenses, Organic Certifications, and Substantial Assets

Acquisition marks the largest acquisition to date with multi-state processing licenses, compounding pharmacy license, and advanced equipment MELBOURNE, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) — via IBN — Branded Legacy, Inc. (OTC.PK: BLEG), a key player in the biotech industry, is excited to announce its largest acquisition to date, MariJ Pharmaceuticals, Inc. The deal significantly expands Branded Legacy’s asset base and intellectual property portfolio with a landmark acquisition. The deal brings an impressive suite of physical and IP assets including a compounding pharmacy license, a cutting-edge supercritical CO2 extraction unit, inventory of certified organic refined CBD, a fleet of licensed and permitted vehicles – ingeniously modified to house a complete extraction facility, a state-of-the-art refinement lab, and...

Continue reading

AutoZone 1st Quarter Domestic Same Store Sales Increase 1.2%; EPS Increases to $32.55

MEMPHIS, Tenn., Dec. 05, 2023 (GLOBE NEWSWIRE) — AutoZone, Inc. (NYSE: AZO) today reported net sales of $4.2 billion for its first quarter (12 weeks) ended November 18, 2023, an increase of 5.1% from the first quarter of fiscal 2023 (12 weeks). Same store sales, or sales for our domestic and international stores open at least one year, are as follows:      Constant Currency  12 Weeks   12 Weeks*       Domestic 1.2 %   1.2 %International 25.1 %   10.9 %Total Company 3.4 %   2.1 %* Excludes impacts from fluctuations of foreign exchange rates.      For the quarter, gross profit, as a percentage of sales, was 52.8%, an increase of 279 basis points versus the prior year. The increase in gross margin was driven by 208 basis point ($83 million net) non-cash LIFO favorability, with the remaining leverage primarily...

Continue reading

Lands’ End Announces Third Quarter Fiscal 2023 Results

DODGEVILLE, Wis., Dec. 05, 2023 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) today announced financial results for the third quarter ended October 27, 2023. Andrew McLean, Chief Executive Officer, stated, “Our third quarter results reflect the continued strong execution of our solutions-based strategy to deliver compelling product for our customers and value to our shareholders. Our deliberate efforts to generate more profitable sales resulted in increased gross profit dollars and gross margin expansion of approximately 700 basis points and drove Adjusted EBITDA above the high end of our guidance range. We continued to build on our positive momentum, injecting newness across our assortment and increasing inventory turns, resulting in a 25% reduction in year-over-year inventory. Looking ahead, by continuing to play to our strengths...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.